An in-situ vaccination strategy combining Flt3L, radiotherapy and poly-IC:LC was able to recruit activated, cross-presenting DCs to the tumour and increased a PD1+CD8+ T cell-population in non-responding patients. This evidence concerns the gene FLT3LG and neoplasm.